Patent SG-11201908296V-A (SG)
Title: Biomarkers for cancer therapeutics
Inventor: GANSERT JENNIFER LORRAINE
IPC: G01N33/574
Filed: 2018-04-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo Holollm oloiloionomo oimIE (10) International Publication Number WO 2018/201028 Al (51) International Patent Classification: G01N 33/50 (2006.01) A61K 39/395 (2006.01) G01N 33/68 (2006.01) A61K 35/763 (2015.01) G01N 33/574 (2006.01) (21) International Application Number: PCT/US2018/029915 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,746 28 April 2017 (28.04.2017) US (71) Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320 (US). (72) Inventors: GANSERT, Jennifer Lorraine; 337 Long- branch Road, Simi Valley, CA 93065 (US). ANDERSON, Abraham Antonio; 3494 Woodcliff Road, Sherman Oaks, CA 91403 (US). GORSKI, Kevin; 28 Curlew Way, Nova- to, CA 94949 (US). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 GC N O O 1-1 N 00 O 1-1 N O (74) Agent: JAVIER, Teofilo et al.; Lathrop Gage LLP, 28 State Street, 7th Floor, Boston, MA 02109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BIOMARKERS FOR CANCER THERAPEUTICS (57) : Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy com- prising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.